Cardinal Health (CAH)
(Delayed Data from NYSE)
$106.36 USD
+3.78 (3.68%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $106.31 -0.05 (-0.05%) 5:56 PM ET
3-Hold of 5 3
A Value A Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$106.36 USD
+3.78 (3.68%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $106.31 -0.05 (-0.05%) 5:56 PM ET
3-Hold of 5 3
A Value A Growth D Momentum A VGM
Zacks News
5 Stocks Favored by Brokers Amid the Current Turbulence
by Maharathi Basu
We believe that stocks like CVR Energy (CVI), Delek US Holdings (DK), Bread Financial (BFH), Dish Network (DISH) and Cardinal Health (CAH) should be on an investor's watchlist.
Here's Why Cardinal Health (CAH) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Cardinal Health (CAH) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Cardinal (CAH) Down 2.7% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Cardinal (CAH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Reasons to Retain Cardinal Health (CAH) in Your Portfolio
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.
Why Cardinal Health (CAH) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Cardinal Health's (CAH) Latest Launch to Enhance Neonatal Feeding
by Zacks Equity Research
Cardinal Health's (CAH) latest offering is likely to help premature and newborn infants develop the oral coordination skills important for the faster transition to independent feeding.
AngioDynamics' (ANGO) New FDA Recognition to Boost Treatment
by Zacks Equity Research
The FDA's grant of the Breakthrough Device designation for AngioDynamics' (ANGO) AngioVac is likely to remove thrombus and embolic material and minimize blood loss via blood recirculation.
Patterson Companies (PDCO) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about Patterson Companies' (PDCO) broad product line.
West Pharmaceutical (WST) Hits 52-Week High: More Room to Grow?
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.
Compared to Estimates, Cardinal (CAH) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Cardinal (CAH) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Cardinal Health (CAH) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Cardinal (CAH) delivered earnings and revenue surprises of 4.73% and 2%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Cardinal Health (CAH) Beats on Q4 Earnings, Ups '24 EPS View
by Zacks Equity Research
Cardinal Health's (CAH) fiscal fourth-quarter results benefit from the Pharmaceutical segment's solid performance.
Time to Buy These Medical Stocks as Earnings Approach
by Shaun Pruitt
Quarterly results from large retailers will highlight this week's earnings lineup but there are a few healthcare companies that investors will want to pay attention to as well.
Prescribing Profits: 3 Stocks to Ride the Healthcare Relative Strength
by Ethan Feller
Over the last month, Healthcare has been the second strongest sector in the market
3 Reasons to Retain DaVita (DVA) Stock to Your Portfolio
by Zacks Equity Research
DaVita's (DVA) strength in its DaVita Kidney Care raises optimism about the stock.
Reasons to Add Patterson Companies (PDCO) to Your Portfolio Now
by Zacks Equity Research
Investors remain optimistic about Patterson Companies (PDCO) on the back of its broad product line.
Deere (DE) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Deere's (DE) third-quarter fiscal 2023 results are likely to reflect favorable farm fundamentals, partially offset by inflated costs and supply-chain headwinds.
Asensus Surgical (ASXC) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Asensus Surgical (ASXC) delivered earnings and revenue surprises of -12.50% and 3.84%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for Cardinal Health (CAH)
by Zacks Equity Research
Cardinal Health (CAH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Is a Beat Likely for Cardinal Health (CAH) in Q4 Earnings?
by Zacks Equity Research
Cardinal Health's (CAH) fiscal fourth-quarter 2023 results are expected to reflect solid performance in the Pharmaceutical segment.
Henry Schein (HSIC) Surpasses Q2 Earnings Estimates
by Zacks Equity Research
Henry Schein (HSIC) delivered earnings and revenue surprises of 4.80% and 0.38%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
3 MedTech Stocks Likely to Top Estimates This Earnings Season
by Urmimala Biswas
MedTech companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how EYE, CAH and HSIC are poised ahead of their earnings releases.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Will Cardinal (CAH) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Cardinal (CAH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.